Last reviewed · How we verify

Control (bupivacaine)

Kasr El Aini Hospital · FDA-approved active Small molecule

Control (bupivacaine) is a Local anesthetic (amide) Small molecule drug developed by Kasr El Aini Hospital. It is currently FDA-approved for Local anesthesia for infiltration, nerve blocks, and regional anesthesia, Epidural and spinal anesthesia. Also known as: Marcaine.

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local anesthesia for infiltration, nerve blocks, and regional anesthesia, Epidural and spinal anesthesia.

At a glance

Generic nameControl (bupivacaine)
Also known asMarcaine
SponsorKasr El Aini Hospital
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, thereby stabilizing the neuronal membrane and preventing depolarization. This action blocks conduction of nerve impulses in sensory, motor, and autonomic nerves depending on the concentration and route of administration. Its longer duration of action compared to other local anesthetics makes it suitable for both infiltration anesthesia and regional nerve blocks.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Control (bupivacaine)

What is Control (bupivacaine)?

Control (bupivacaine) is a Local anesthetic (amide) drug developed by Kasr El Aini Hospital, indicated for Local anesthesia for infiltration, nerve blocks, and regional anesthesia, Epidural and spinal anesthesia.

How does Control (bupivacaine) work?

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.

What is Control (bupivacaine) used for?

Control (bupivacaine) is indicated for Local anesthesia for infiltration, nerve blocks, and regional anesthesia, Epidural and spinal anesthesia.

Who makes Control (bupivacaine)?

Control (bupivacaine) is developed and marketed by Kasr El Aini Hospital (see full Kasr El Aini Hospital pipeline at /company/kasr-el-aini-hospital).

Is Control (bupivacaine) also known as anything else?

Control (bupivacaine) is also known as Marcaine.

What drug class is Control (bupivacaine) in?

Control (bupivacaine) belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is Control (bupivacaine) in?

Control (bupivacaine) is FDA-approved (marketed).

What are the side effects of Control (bupivacaine)?

Common side effects of Control (bupivacaine) include Systemic toxicity (CNS effects: tremor, seizures, loss of consciousness), Cardiovascular effects (hypotension, bradycardia, arrhythmias), Local reactions (pain, erythema at injection site), Allergic reactions (rare with amide local anesthetics).

What does Control (bupivacaine) target?

Control (bupivacaine) targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing